Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. [electronic resource]
Producer: 20130722Description: 927-39 p. digitalISSN:- 1873-4286
- Apoptosis -- drug effects
- Blotting, Western
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Chromatography, Liquid
- Drug Synergism
- Enzyme-Linked Immunosorbent Assay
- Erlotinib Hydrochloride
- Flow Cytometry
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms -- drug therapy
- Molecular Targeted Therapy
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Phosphatidylethanolamine Binding Protein
- Phosphorylation -- drug effects
- Protein Kinase Inhibitors -- administration & dosage
- Quinazolines -- administration & dosage
- Sorafenib
- Tandem Mass Spectrometry
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.